Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PERRIGO Co plcPRGO · Entity 4516 | Director | May 13, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PERRIGO Co plc
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 34,435 |
Ending reported balance
After 2026-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-14 · Exercise / conversion · Acquired 7,305 · Balance 37,942 Row 2 · 2026-05-14 · Tax withholding · Disposed 3,507 · Balance 34,435 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,681 |
Reported balance
After 2026-05-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-13 · Grant · Acquired 16,681 · Balance 16,681 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on May 13 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-14 · Exercise / conversion · Disposed 7,305 · Balance 0 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026. |
| Ordinary SharesSEC Table I · non-derivative | Indirectby Approved Retirement Fund | 1,198 |
Reported balance
Holding disclosure · report date 2026-05-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,198 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.
F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on May 13 2027.
F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 74,204 · Balance 6,009 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 6,009 · Balance 0 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2028-04-30 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2029-04-29 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2030-04-27 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.15 · Expires 2032-04-25 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-23 · Disposition to issuer · Disposed 28,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2033-05-01 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-23 · Disposition to issuer · Disposed 22,044 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2034-05-07 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-23 · Disposition to issuer · Disposed 23,576 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2035-05-18 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-23 · Disposition to issuer · Disposed 24,258 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2036-06-11 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-23 · Disposition to issuer · Disposed 13,398 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2020 Filed May 20, 2020 00:41 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 6,054 | $52.76 | $319,409.04 |
DisclosureSEC source: 0001585364-20-000065 · wf-form4_158993525971538.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2019. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:49 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 5,804 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-20-000053 · wf-form4_158923013441164.xml · derivative · entry 3 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,804 Underlying: Ordinary Shares · 5,804 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 23:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $30.14 | $0.00 |
DisclosureSEC source: 0001179110-20-005304 · edgar.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 23:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005304 · edgar.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,206 Read SEC document |
| May 17, 2019 Filed May 20, 2019 22:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,673 | $20.19 | $53,967.60 |
DisclosureSEC source: 0001179110-19-006410 · edgar.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,571 F1 · price: This transaction was executed in multiple trades at prices from $20.181000 to $20.2274. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 16, 2019 Filed May 20, 2019 22:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 1,327 | $21.00 | $27,867.00 |
DisclosureSEC source: 0001179110-19-006410 · edgar.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,244 Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:58 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 3,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-19-000066 · wf-form4_155812309988989.xml · derivative · entry 5 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,971 shares Expires 2019-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2018. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:58 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 6,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-19-000066 · wf-form4_155812309988989.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,054 Underlying: Ordinary Shares · 6,054 shares Expires 2020-05-15 F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:58 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 1,907 | $49.55 | $94,491.85 |
DisclosureSEC source: 0001585364-19-000066 · wf-form4_155812309988989.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,289 Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:58 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 3,971 | $49.55 | $196,763.05 |
DisclosureSEC source: 0001585364-19-000066 · wf-form4_155812309988989.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2018. Read SEC document |
| April 30, 2019 Filed May 2, 2019 22:28 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001179110-19-005465 · edgar.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2029-04-29 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 30, 2019 Filed May 2, 2019 22:28 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005465 · edgar.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,571 Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:05 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 4,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-18-000040 · wf-form4_152849191938483.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,265 shares Expires 2018-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:05 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 2,218 | $73.22 | $162,401.96 |
DisclosureSEC source: 0001585364-18-000040 · wf-form4_152849191938483.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,225 Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:05 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 4,265 | $73.22 | $312,283.30 |
DisclosureSEC source: 0001585364-18-000040 · wf-form4_152849191938483.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on June 6, 2017. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:43 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 3,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-18-000039 · wf-form4_152658977891770.xml · derivative · entry 3 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,971 Underlying: Ordinary Shares · 3,971 shares Expires 2019-05-15 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| May 01, 2018 Filed May 3, 2018 22:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $24.43 | $0.00 |
DisclosureSEC source: 0001179110-18-006193 · edgar.xml · derivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 22:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006193 · edgar.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,186 Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 18:18 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 4,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-17-000091 · wf-form4_149694586327915.xml · derivative · entry 3 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,265 Underlying: Ordinary Shares · 4,265 shares Expires 2018-06-06 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 16:37 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 3,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001585364-17-000089 · wf-form4_149642142927368.xml · derivative · entry 4 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,263 shares Expires 2017-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on May 19, 2016. F3 · derivative.exercise_date: The Reporting Person had voluntarily agreed to postpone the vesting of this award until such time as the Issuer is current in its filings under the Securities Exchange Act of 1934. F3 · derivative.expiration_date: The Reporting Person had voluntarily agreed to postpone the vesting of this award until such time as the Issuer is current in its filings under the Securities Exchange Act of 1934. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 16:37 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 1,697 | $72.85 | $123,626.45 |
DisclosureSEC source: 0001585364-17-000089 · wf-form4_149642142927368.xml · nonDerivative · entry 2 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,178 Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 16:37 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 3,263 | $72.85 | $237,709.55 |
DisclosureSEC source: 0001585364-17-000089 · wf-form4_149642142927368.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on May 19, 2016. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007544 · edgar.xml · nonDerivative · entry 1 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| May 19, 2016 Filed May 19, 2017 17:27 UTC Amendment | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 3,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-17-000058 · wf-form4a_149521481631250.xml · derivative · entry 3 O'Connor Donal · CIK 0001625377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,263 Underlying: Ordinary Shares · 3,263 shares Expires 2017-05-19 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: The Reporting Person has voluntarily agreed to postpone the vesting of this award until such time as the Issuer is current in its filings under the Securities Exchange Act of 1934. F2 · derivative.expiration_date: The Reporting Person has voluntarily agreed to postpone the vesting of this award until such time as the Issuer is current in its filings under the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.